Comparative Pharmacology
Head-to-head clinical analysis: MIRALUMA versus SODIUM IODIDE I 123.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRALUMA versus SODIUM IODIDE I 123.
MIRALUMA vs SODIUM IODIDE I 123
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MIRALUMA (garadacimab) is a monoclonal antibody that binds to activated factor XII (FXIIa) and inhibits its activity, thereby blocking the contact activation pathway of the coagulation cascade. This prevents the generation of bradykinin, reducing vascular permeability and swelling in hereditary angioedema (HAE).
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
MIRALUMA (mirvetuximab soravtansine) is administered intravenously at 6 mg/kg adjusted ideal body weight (AIBW) once every 3 weeks until disease progression or unacceptable toxicity.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
None Documented
None Documented
20 hours; prolonged to 30-40 hours in renal impairment requiring dose adjustment
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
90% renal as unchanged drug; 10% biliary/fecal
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical